PRO 140
PRO 140 is a pharmaceutical drug with 11 clinical trials. Historical success rate of 71.4%.
Success Metrics
Based on 5 completed trials
Phase Distribution
Phase Distribution
1
Early Stage
9
Mid Stage
0
Late Stage
Highest Phase Reached
Phase 2Trial Status & Enrollment
50.0%
5 of 10 finished
50.0%
5 ended early
0
trials recruiting
11
all time
Detailed Status
Development Timeline
Analytics
Development Status
Trials by Phase
Trials by Status
Recent Activity
An Extension Protocol for Subjects Who Successfully Completed PRO140_CD02 or PRO140_CD02_Open Label Study
PRO 140 in Treatment-Experienced HIV-1 Subjects
A Study of Acute Graft-Versus-Host Disease (GVHD) in Patients Undergoing Allogeneic Stem-Cell Transplantation
Treatment Substitution With PRO 140 Monotherapy in Adult Subjects With HIV-1 Infection
Safety and Tolerability of PRO 140 in HIV Uninfected Male Volunteers
Clinical Trials (11)
An Extension Protocol for Subjects Who Successfully Completed PRO140_CD02 or PRO140_CD02_Open Label Study
PRO 140 in Treatment-Experienced HIV-1 Subjects
A Study of Acute Graft-Versus-Host Disease (GVHD) in Patients Undergoing Allogeneic Stem-Cell Transplantation
Treatment Substitution With PRO 140 Monotherapy in Adult Subjects With HIV-1 Infection
Safety and Tolerability of PRO 140 in HIV Uninfected Male Volunteers
Randomized, Double-Blind, Placebo-Controlled Trial, Followed by Single-Arm Treatment of PRO 140
An Expanded Access Protocol for a Single Subject Who Has Completed 24-Weeks of Treatment in PR0140_CD02 Study
PRO 140 for Human Immunodeficiency Virus Infection
PRO 140 for Human Immunodeficiency Virus
A Trial of Observed Long-acting, Anti-HIV Treatment With a Monoclonal CCR5 Antibody (PRO 140) as an Adjunct to a New, Optimized, Oral Antiretroviral Regimen in HIV-infected Injection Drug Users With Viral Rebound and Documented Poor Adherence
PRO 140 by IV Administration in Adults With HIV-1 Infection
All 11 trials loaded
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 11